Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
This blog post provides a comprehensive overview of psoriasis in individuals with skin of color. It explores the prevalence of psoriasis in different ethnic groups worldwide and highlights potential underestimations due to healthcare barriers. The article discusses genetic variations in psoriasis susceptibility among ethnic groups and the challenges in diagnosing psoriasis in darker-skinned individuals. It emphasizes the need for inclusive dermatology education and resources that incorporate skin of color to improve clinical competency. The impact of psoriasis on quality of life, specifically in non-white individuals, and the importance of developing better measurement tools for diverse ethnicities are examined. The blog post also addresses treatment approaches for psoriasis in diverse ethnic populations and the ongoing efforts to include patients of different ethnicities in clinical trials.
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
An article recently published in the Journal of Allergy and Clinical Immunology suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1,115 of whom had been diagnosed with COVID-19.
In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.
Soon after COVID-19 was declared a pandemic, the question if particular patient groups – those with immune-mediated inflammatory disease (IMID) and/or those on an immunosuppressant treatment – are at higher risk to become infected and/or are at risk for developing a more severe course of the disease.
The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics